{"id":14468,"date":"2021-11-29T17:04:00","date_gmt":"2021-11-29T17:04:00","guid":{"rendered":"https:\/\/www.upjs.sk\/pracoviska\/tip\/sp\/casprot\/research\/26122-2\/"},"modified":"2024-01-01T21:18:05","modified_gmt":"2024-01-01T21:18:05","slug":"26122-2","status":"publish","type":"page","link":"https:\/\/www.upjs.sk\/pracoviska\/tip\/en\/sp\/casprot\/research\/26122-2\/","title":{"rendered":"Introducing CasProt Protein research during the seminary at the occasion of 100th-anniversary of prof. Bartik \u2013 the founder of Biochemistry in Kosice"},"content":{"rendered":"
Dr. Zoldak presented recent progress in understanding of protein aggregation. Protein aggregation is an adverse effect that affects a wide range of areas. The most serious is the aggregation leading to the development of life-threatening diseases. Such diseases include immunoglobulin G (IgG) light chain amyloidosis or multiple myeloma. In this work, a light chain (hLC) causing renal multiple myeloma was selected to study the effect of reducing agents on the rate of hLC aggregation and the size of aggregates formed.<\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Dr. Zoldak presented recent progress in understanding of protein aggregation. Protein aggregation is an adverse effect that affects a wide range of areas. The most serious is the aggregation leading to the development of life-threatening diseases. Such diseases include immunoglobulin G (IgG) light chain amyloidosis or multiple myeloma. In this work, a light chain (hLC) … Continued<\/a><\/p>\n","protected":false},"author":1,"featured_media":14461,"parent":14451,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"class_list":["post-14468","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":{"acf_link_na_externy_obsah":""},"yoast_head":"\n